Abstract. Periostin/OSF2 is a ligand for αvβ3 and αvβ5 integrins and activates the Akt/PKB pathway. Recent reports of periostin/OSF2 gene disrupted mice indicate that periostin/OSF-2 plays an important role in implantation. Quantitative RT-PCR revealed that the expression of periostin/OSF-2 mRNA in rat uteri was reduced to approximately 10% at 12 h after 17β-estradiol (E2) injection, but was not changed after progesterone (P) injection. RT-PCR revealed the expression of periostin/OSF-2 in human endometrium, cultured human endometrial stromal cells (ESCs), and cultured human endometrial epithelial cells. In ESCs, the expression of periostin/OSF-2 mRNA was reduced to approximately 50% at 6 h after E2 treatment. The amount of periostin/OSF2 mRNA in human endometrium significantly increased during midproliferative and early secretory phases of menstrual cycle, and decreased during late-proliferative, mid-secretory and late secretory phases. The expression of periostin/OSF2 mRNA significantly decreased in ESCs decidualized by treatment with E2 and P for 7 and 11 days. By immunohistochemistry, the expression of periostin/OSF-2 was strongly detected in endometrial stromal cells during early proliferative, mid-proliferative and early secretory phases, and was strongly detected in endometrial epithelial cells during late secretory phase. This study demonstrated that the expression of periostin/OSF-2 is regulated by ovarian steroid hormones in rat uterus and human endometrium.
PERIOSTIN, formerly named osteoblast-specific factor-2 (OSF-2), was first identified in a mouse osteoblast-like cell line using subtractive hybridization techniques and was considered bone-specific [1] . Human periostin/OSF-2 was cloned from human osteosarcoma and placenta [2] . Several investigators have reported that periostin/OSF-2 is expressed not only in osteoblasts but also in normal adult tissues, including aorta, stomach, lower gastrointestinal tract, placenta, uterus, and breast [3, 4] . Periostin/OSF-2 has a typical signal peptide at the N-terminal end, suggesting that it is a secreted protein [1] . Periostin/OSF-2 is highly homologous to βigH3 and fasciclin I, which promote the adhesion and spreading of cells [5, 6, 7] . Purified recombinant periostin/OSF-2 has been shown as a ligand for αvβ3 and αvβ5 integrins promoting integrindependent cell adhesion and motility [4] and activating the Akt/PKB pathway [8] .
Recently, Rios et al. generated periostin null mice [9] . Although periostin is widely expressed in many developing organs, the embryos of periostin null mice are normal, suggesting that periostin may not be critical for early mouse development. Fourteen percent of periostin null mice die before weaning. Postnatally, the growth of periostin null mice is severely retarded. Trabecular bone in adult periostin null mice was sparse, but overall bone growth was unaffected. Incisor enamel defects were observed. Although male periostin null mice were fertile, the females were infertile. Hormonal responses and ovarian folliculogenesis were intact in female periostin null mice. Histologically, the female reproductive organs appeared normal, but were propor-tionally undersized. When the oviducts of plugged periostin null mice were sectioned, both two-cell and four-cell zygotes were found, indicating that periostin/ OSF-2 plays an important role in implantation.
In the present study, we investigate the expression and regulation of periostin/OSF-2 gene in rat uterus and primary cultured human endometrial cells.
Materials and Methods

Animals and treatment
Female Sprague-Dawley rats of 8-12 weeks old were used in this study. All animals were maintained in accordance with institutional guidelines for the care and use of laboratory animals. To investigate genes regulated by progesterone, the uteri of ovariectomized rats were used. All rats were sacrificed 2 weeks after ovariectomy. The ovariectomized rats were administered 20 µg of 17-β estradiol (E) or 2 mg of progesterone (P) dissolved in corn oil. Control rats were administered corn oil only by subcutaneous injection and sacrificed 2 h after injection. E or P treated rats were sacrificed 2 h, 12 h, 24 h and 48 h after injection. For reverse transcription-polymerase chain reaction (RT-PCR) and quantitative real-time RT-PCR, rat tissue including uterus were removed, frozen rapidly and stored at -80°C until use. For immunohistochemistry, the uteri were fixed in 4% (vol/vol) paraformaldehyde, embedded in paraffin and sectioned at a thickness of 20 µm.
Patients and samples
Endometrial tissues were obtained from patients undergoing hysterectomy for benign gynecological conditions. In total 60 woman aged 40-48 years were recruited to the present study. All patients had regular menstrual cycles, and none had received hormonal treatment for at least 6 months before surgery. The tissues were collected under sterile conditions and processed for primary cell cultures. The menstrual cycle stage was determined according to the patients' menstrual history and standard histological criteria [10] . The experimental procedures were approved by the institutional review board of the University of Tokyo and signed informed consent for use of the endometrial tissue was obtained from each patient.
Isolation and culture of human endometrial stromal and epithelial cells
Isolation and culture of human endometrial stromal cells (ESCs) and endometrial epithelial cells (EECs) were undertaken as described previously [11, 12] . Fresh endometrial biopsy specimens collected in sterile medium were rinsed to remove blood cells. The tissues were minced into small pieces and incubated in DMEM/F-12 containing type I collagenase (0.25%) and deoxynuclease I (15 U/mL) for 120 min at 37°C. The resultant dispersed endometrial cells were separated by filtration through a 40-µm nylon cell strainer (Becton Dickinson, Franklin Lakes, NJ, USA). Endometrial epithelial glands that remained intact were retained by the strainer, whereas dispersed ESCs passed through the strainer into the filtrate.
ESCs in the filtrate were collected by centrifugation and resuspended in phenol-red free DMEM/F-12 containing 10% charcoal-stripped FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 0.25 µg/mL amphotericin B. ESCs were seeded in a 100-mm culture plate and kept at 37°C in a humidified 5% CO 2 -/95% air atmosphere. At the first passage, the cells were plated into 6-well culture plates (Becton Dickinson) at a density of 2 × 10 5 cells/mL. The cells reached confluence in 2 and 3 days, and were used for the experiments.
EECs were collected by back-washing the strainer with DMEM/F-12 containing 10% charcoal-stripped FBS, seeding in a 100-mm plate, and incubation at 37°C for 60 min to allow contaminated ESCs to attach to the plate wall. The nonattached EECs were recovered and cultured in the culture medium at a density of 2 × 10 5 cells/mL into 12-well culture plates. The cells, reached confluence in 3 or 4 days, were then used for experiments. To investigate the response of periostin/ OSF2 expression to estrogen and progesterone, the cells were cultured in the presence of 1 × 10 -7 M 17β-estradiol (E2) or 1 × 10 -7 M progesterone (P) for the indicated periods (3 h, 6 h, 12 h, 24 h) and collected for quantitative RT-PCR. In order to investigate the relationship of decidualization of human endometium and the expression of periostin/OSF2, cultured endometrial stromal cells were treated with both E2 and P for 3, 7 and 11 days.
Total RNA extraction and cDNA synthesis Total RNA was isolated from rat tissues using ISOGEN (Nippon Gene, Tokyo, Japan) following the manufacturer's instructions. First-strand cDNA synthesis was performed with 0.5 µg total RNA using ReverTra Ace α kit (Toyobo, Osaka, Japan) following the manufacturer's instructions. PCR amplification was performed using 25 µL with KOD-dash DNA polymerase (Toyobo, Osaka, Japan) following the manufacturer's instructions.
Reverse transcription-polymerase chain reaction (RT-PCR)
For RT-PCR, 0.5 µL-aliquots of cDNA were used. The oligonucleotides sequences of primers are shown in Table 1 . All PCR products were electrophoresed on a 2% agarose gel and cloned into the vector pCR-2.1-TOPO (TOPO TA-cloning kit, Invitrogen, Carlsbad, CA, USA). The sequences of all PCR products were confirmed using an ABI PRISM 310 genetic analyzer (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time reverse transcription-polymerase chain reaction
To assess periostin/OSF-2 mRNA expression, quantitative real-time RT-PCR and data analysis were performed using LightCycler (Roche Diagnostic GmbH, Mannheim, Germany). Amplifications were carried out using Lithos pPCR HotStart Master Mix (Nippon Gene) according manufacturer's instructions. The reaction mixture (total 20 µL) consists of 0.5 µl of 1 : 500 dilution of SYBR Green I, 0.5 µmol/L of each primer, 2 × Master Mix. The cDNAs were diluted 1 : 10 in sterile water and 3 µL aliquots were used for quantitative real-time RT-PCR. Expression of periostin/OSF-2 mRNA was normalized to RNA loading for each sample using GAPDH mRNA as an internal standard. The primers for rat periostin/OSF-2, human periostin/OSF-2, rat GAPDH and human GAPDH were the same as those used for standard PCR. These PCR conditions were confirmed by melting curve analysis.
Immunohistochemistry of human endometrium
Immunohistochemical procedures on human endometrial tissue were performed using paraffin-embedded sections. The sections were dipped into xylene twice, 100% ethanol twice and 95% ethanol twice. After blocking with 3% H 2 O 2 in methanol and 10% goat serum, the sections were incubated with anti-periostin/ OSF-2 antibody (BioVendor Lab. Med. Inc., Candler, NC, USA) and 1 µg/mL rabbit IgG control at room temperature for over night, and then with biotinylated second antibody (antirabbit IgG + IgA + IgM) for 1 h at room temperature. The samples were then incubated with streptavidin conjugated with horseradish peroxidase (Histofine SAB-PO kit; Nichirei, Inc., Tokyo, Japan), and visualized using a peroxidase substrate kit with 3,3'-diamino benzidine (Histofine SAB-PO kit; DAB substrate kit; Nichirei, Inc., Tokyo, Japan).
Statistical analysis
The results are presented as the mean ± SEM. They were analyzed by one-way analysis of variance (ANO-VA) with post hoc analysis for multiple comparison tests. Statistical significance was accepted at P<0.05.
Results
The expression of periostin/OSF-2 mRNA was detected in brain stem, lung, spleen, ovary, muscle, small intestine and uterus in rat by RT-PCR (Fig. 1) . Periostin/ OSF-2 mRNA expression in rat uterus was quantified by quantitative RT-PCR (Fig. 2) . Quantitative RT-PCR revealed that the expression of periostin/OSF-2 mRNA in rat uterus was reduced to approximately 10% at 12 h and 24 h, and 35% at 48 h after 17-β estradiol (E2) injection ( Fig. 2A) , but was unchanged after progesterone (P) injection (Fig. 2B) . The expression of periostin/OSF-2 mRNA, estrogen receptor α and progesterone receptor was detected in human endometrium, cultured human ESCs and cultured human EECs by RT-PCR (Fig. 3) . The responses of human periostin/OSF-2 mRNA in ESCs and EECs treated with E2 or P were quantified by quantitative RT-PCR (Fig. 4, 5) . The expression of periostin/OSF-2 Fig. 1 . Periostin/OSF-2 mRNA expression in rat tissues was detected by RT-PCR. PCR products derived from GAPDH mRNA were used as controls.
Fig. 2.
Amount of periostin/OSF-2 mRNA in rat uterus was quantified by real time RT-PCR. A, Periostin/OSF-2 mRNA expression in uteri from ovariectomized rats injected with 17-β estradiol (E2). B, Periostin/OSF-2 mRNA expression in uteri from ovariectomized rats injected with progesterone (P). All results were normalized to the amount of GAPDH mRNA. Periostin/OSF-2 mRNA is shown as fold increase compared with the amount of transcripts in uteri from rats injected with corn oil only (control). Mean ± SEM (*: p<0.05). mRNA was reduced to approximately 78% at 3 h and 50% at 6 h after E2 treatment in ESCs (Fig. 4A) , but was unchanged in EECs treated with E2 (Fig. 4B ). There were no significant changes in the expression of human periostin/OSF-2 with P in ESCs and EECs (Fig. 5) . The amount of periostin/OSF-2 mRNA in human endometrium significantly increased during the midproliferative phase and early secretory phase of the menstrual cycle, and decreased during the late proliferative phase, mid-secretory phase and late secretory phase (Fig. 6 ). The expression of periostin/OSF2 mRNA significantly decreased in ESCs decidualized by treatment with both E2 and P for 7 and 11 days (Fig. 7) .
Immunohistochemistry with anti-periostin/OSF-2 antibody demonstrated that human periostin/OSF-2 was expressed in endometrial epithelial cells and stromal cells in all phases of the menstrual cycle (Fig. 8) .
No staining was detected with control IgG. Immunoreactivity of periostin/OSF-2 was strongly detected in endometrial stromal cells during the early proliferative phase, mid-proliferative phase and early secretory phase of menstrual cycle. During the late secretory phase, immunoreactivity of periostin/OSF-2 was strongly detected in endometrial epithelial cells, whereas it was weakly detected in endometrial stromal cells.
Discussion
This study demonstrated that periostin/OSF-2 was expressed in rat uterus and human endometrium and regulated by estrogen. In rat uterus, the expression of periostin/OSF-2 mRNA was down-regulated by E2, Fig. 6 . Periostin/OSF-2 mRNA expression in human endometrium throughout the menstrual cycle. All results were normalized to the amount of GAPDH mRNA. Periostin/OSF-2 mRNA is shown as fold increase compared with the amount of transcripts in human endometrium during early proliferative phase. a,b,c Mean ± SEM with different superscripts are significantly different (p<0.05). Fig. 7 . Amount of periostin/OSF-2 mRNA in cultured human endometrial stromal cells (ESCs) was quantified by real time RT-PCR. ESCs were treated with both 17-β estradiol (E2) and progesterone (P) for 3 days (Day 3), 7 days (Day 7) and 11 days (Day 11). All results were normalized to the amount of GAPDH mRNA. Periostin/OSF-2 mRNA is shown as fold increase compared with the amount of transcripts in ESCs treated with E2 and P for 3 days. Mean ± SEM (*: p<0.05). but not by P (Fig. 2) . Although the expression of periostin/OSF-2 was not regulated by E2 in cultured EECs, periostin/OSF-2 mRNA expression was down-regulated by E2 as in the rat uterus in cultured ESCs (Fig. 4) . Estrogen plays important roles in the reproductive system and the uterus and endometrium are target tissues for estrogen. The actions of estrogen are mediated by the estrogen receptors, which are members of the nuclear receptor superfamily [13] . Our data show that expression of periostin/OSF-2 mRNA is low during the late proliferative phase, mid-secretory phase and late secretory phase, when estrogen secretion increases, indicating that the expression of periostin/OSF-2 is regulated by estrogen in the human endometrium. Gillan et al. reported that periostin/OSF-2 functioned as a ligand for αvβ3 and αvβ5 integrins with ovarian carcinoma cells [4] , and Bao et al. showed that periostin/OSF-2 activated the Akt/PKB pathway via αvβ3 integrins [8] . Integrins are adhesion molecules which participate in the adhesion of cell-to-cell or between cells and components of the extracellular matrix. Our results suggest that periostin/OSF-2 may mediate estrogen action via integrin and the Akt/PKB pathway in the endometrium.
It has been reported that the function of periostin/ OSF-2 is related to remodeling of human tissue. In bone, periostin/OSF-2 was one of the genes expressed in the early stage of bone fracture healing in a mouse model [14] . Lindner et al. showed that the expression of periostin/OSF-2 mRNA was up-regulated in rat carotid arteries after balloon injury and was related to smooth muscle differentiation [15] . The periostin/ OSF-2 gene was highly expressed in a heart failure model [16] . Katsuragi et al. reported that over-expression of the periostin/OSF-2 gene led to cardiac dysfunction in a rat model, while its inhibition resulted in improved left ventricular function and a significant increase in survival rate [17] .
Our data indicate that periostin/OSF-2 may be related to remodeling of the endometrium as well as the tissues reported previously. During the menstrual cycle, the structure of the endometium changes dramatically. In the proliferative phase, the endometrium thickens, mainly regulated by estrogen. After ovulation, the endometrium differentiates for implantation, mainly regulated by estrogen and progesterone. In the present study, quantitative RT-PCR revealed that the expression of perisotin/OSF2 mRNA decreased during middle and late phase of menstrual cycle, which is confirmed by the results of in vitro cultured endometrial stromal cells decidualized by long term treatment with both estrogen and progesterone (Fig. 7) . The expression of periostin/OSF-2 mRNA increased after the menstrual period, as seen during the early and middle parts of the proliferative phase. These data indicate the participation of periostin/OSF2 in remodeling of the endometrium.
Female periostin null mice are infertile [9] . When the oviducts of plugged periostin null mice were sectioned, both two-cell and four-cell zygotes were found, indicating that periostin/OSF-2 plays a crucial role in implantation. There are two possible targets of periostin/OSF-2 during implantation. One of them is the uterine endometrium. We showed that the expression of periostin/OSF-2 increased during the early secretory phase of the menstrual cycle, which indicates that secreted periostin/OSF-2 may activate the differentiation of the endometrium for implantation. Periostin/OSF-2 has been shown to be a ligand for αvβ3 and αvβ5 integrins promoting integrin-dependent cell adhesion and motility [4, 8] . Lessey et al. reported that the expression of αvβ3 integrin increased in the putative window of implantation, suggesting its role in the establishment of uterine receptiveness [18] . There was no difference in the expression of αvβ3 integrin in women who were pregnant or infertile [19] . It is possible that perisotin/ OSF-2 plays an important role for uterine receptiveness as a ligand for integrins on human endometrium. Another possible target of perisotin/OSF-2 is the trophoblast. Kabir-Salmani et al. reported that αvβ3 integrin was expressed in the core focal adhesions of extravillous trophoblast cells, and that αvβ3 integrin signaling pathways are activated in insulin-like growth factor-I mediated migration of these cells [20] . αvβ3 integrin is expressed in human endometrium at the beginning of pregnancy. In the human trophoblast, αvβ3 integrin is detected in distal, invasive and endovascular extravillous cytotrophoblast [21] .
In conclusion, periostin/OSF-2 is expressed in rat uterus and human endometrium, and is regulated by ovarian steroid hormones. The expression of this gene changes throughout the menstrual cycle. The pattern of periostin/OSF-2 expression indicates that this gene may be related to the function of the endometrium.
